Abacus Bioscience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Abacus Bioscience is a private, preclinical-stage biotech focused on pioneering active immunotherapies that break immune tolerance, a significant barrier in treating cancer and persistent infections. Leveraging advanced computational tools like AlphaFold for drug design, the company is building a pipeline of novel biologics. Operating from the major biotech hub of San Diego, it is positioned to tackle large, underserved markets in oncology and infectious diseases, though it remains an early-stage, pre-revenue venture.

OncologyInfectious Diseases

Technology Platform

Computational design of novel antibody/biologic immunotherapies using AI (e.g., AlphaFold) to overcome immune tolerance.

Opportunities

The company targets massive, growing markets in oncology and chronic infections where overcoming immune tolerance is a major unmet need.

Leveraging AI for drug design offers potential for faster, more rational development of first-in-class therapies.

Risk Factors

High scientific risk of novel mechanism failure, preclinical-stage development risk, dependence on future financing in a challenging capital environment, and intense competition in the immunotherapy landscape.

Competitive Landscape

Abacus operates in the highly competitive fields of cancer immunotherapy and therapeutic vaccines, competing with large pharma and numerous biotechs. Its differentiation hinges on a unique approach to breaking immune tolerance, a challenge many others are also tackling.

More companies in Biologics / Biosimilars →More companies in United States →